Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Foresite Capital Management VI LLC 13F Holdings -- Portfolio & Top Positions (2026-06-30)

Foresite Capital Management VI LLC (CIK 2013341) reported $642.6M across 23 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: CGON ($168.4M, 26.20%), ALMS ($119.5M, 18.60%), SPTX ($38.7M, 6.02%), DNLI ($35.9M, 5.59%), CLDX ($32.7M, 5.09%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1CGONCG Oncology, Inc.$168.4M26.20%2.4MAdded
2ALMSALUMIS INC.$119.5M18.60%4.2MHold
3SPTXSeaport Therapeutics, Inc.$38.7M6.02%1.8MNew
4DNLIDenali Therapeutics Inc.$35.9M5.59%1.4MAdded
5CLDXCelldex Therapeutics, Inc.$32.7M5.09%879,713Added
6AGIOAGIOS PHARMACEUTICALS, INC.$29.1M4.53%785,000Added
7CRVSCorvus Pharmaceuticals, Inc.$27.4M4.26%1.8MHold
8PBLSParabilis Medicines, Inc.$27.3M4.26%999,044New
9GHRSGH Research PLC$25.3M3.93%940,493Added
10JBIOJade Biosciences, Inc.$19.7M3.07%886,667Added
11HNGEHinge Health, Inc.$18.3M2.85%220,400Hold
12KYMRKymera Therapeutics, Inc.$16.8M2.61%146,332Hold
13ATAIAtaiBeckley Inc.$14.5M2.26%2.8MHold
14VSTMVerastem, Inc.$12.0M1.87%3.1MHold
15BEAMBeam Therapeutics Inc.$11.3M1.76%330,000New
16NERVMinerva Neurosciences, Inc.$11.0M1.71%2.0MTrimmed
17AVBPArriVent BioPharma, Inc.$10.5M1.63%301,341New
18AURAAura Biosciences, Inc.$9.5M1.47%1.3MNew
19CRNXCrinetics Pharmaceuticals, Inc.$7.9M1.23%212,010Hold
20RACCResearch Alliance Corp III$3.2M0.50%300,000New
21ZURAZura Bio Ltd$2.7M0.41%450,000Hold
22KLRAKailera Therapeutics, Inc.$826,1250.13%37,500New
23IRONDisc Medicine, Inc.$70,9460.01%970New
24CNTACentessa Pharmaceuticals plc$00.00%0Exited
25OKUROnKure Therapeutics, Inc.$00.00%0Exited

Source: SEC Form 13F filings · as of 2026-06-30